Pharsight

Lexapro patents expiration

LEXAPRO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6916941 ALLERGAN Crystalline composition containing escitalopram
Aug, 2022

(1 year, 1 month ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7420069 ALLERGAN Crystalline composition containing escitalopram
Aug, 2022

(1 year, 1 month ago)

US6916941

(Pediatric)

ALLERGAN Crystalline composition containing escitalopram
Feb, 2023

(7 months ago)

US7420069

(Pediatric)

ALLERGAN Crystalline composition containing escitalopram
Feb, 2023

(7 months ago)

Lexapro is owned by Allergan.

Lexapro contains Escitalopram Oxalate.

Lexapro has a total of 4 drug patents out of which 4 drug patents have expired.

Expired drug patents of Lexapro are:

  • US7420069
  • US6916941*PED
  • US7420069*PED
  • US6916941

Lexapro was authorised for market use on 14 August, 2002.

Lexapro is available in tablet;oral dosage forms.

The generics of Lexapro are possible to be released after 12 May, 2026.

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population (NPP) May 12, 2026

Drugs and Companies using ESCITALOPRAM OXALATE ingredient

Market Authorisation Date: 14 August, 2002

Treatment: NA

Dosage: TABLET;ORAL

How can I launch a generic of LEXAPRO before it's drug patent expiration?
More Information on Dosage

LEXAPRO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic